Pharma CDMO: Why China+1 Could Drive A Multi-Year Growth Story For Indian Companies

India’s pharma CDMO and CDRO sectors are emerging as potential multi-year growth stories as global companies diversify supply chains beyond China. The China+1 strategy is creating opportunities for Indian manufacturers across specialty chemicals and pharmaceuticals, although companies need to invest upfront in R&D and capacity before new contracts translate into revenues. Nishchal Maheshwari, Market Expert, explains the long-term opportunity in the CDMO space and why investors may need patience. The discussion also highlights domestic pharma, AI-led power demand, data centres and New-Age consumption as key themes shaping the market.